Skip to content

The GÖTEBORG prostate cancer screening 2 trial

The GÖTEBORG Prostate Cancer Screening 2 trial (G2): a prospective, randomized, large-scale, population-based prostate cancer screening trial using PSA followed by magnetic resonance imaging of the prostate

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN94604465
Enrollment
40000
Registered
2017-07-10
Start date
2015-09-01
Completion date
Unknown
Last updated
2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer Cancer Malignant neoplasm of prostate

Interventions

By computerized randomization, a random sample of 40,000 men living in Västra Götalandsregionen will gradually be randomized and form the database. If a man decides to participate he visits a clinic

Sponsors

University of Gothenburg
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Male 2. Age 50-60 3. Living in selected municipalities in Västra Götaland, Sweden

Exclusion criteria

Exclusion criteria: Men with prior diagnosis of prostate cancer

Design outcomes

Primary

MeasureTime frame
Rate of overdiagnosis, measured by linking the study population/study database with the Regional Cancer Registry every third month until the study ends

Secondary

MeasureTime frame
Rate of prostate biopsy, defined as the number of events per randomized men measured continuously throughout the study Tertiary outcome measure: Prostate cancer mortality, measured by linkage with the Swedish Causes of Death Registry twice a year until the study ends

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 10, 2026